INmune Bio Inc (INMB) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of INmune Bio Inc $0.65, price $1.93, upside -66.5%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch INmune Bio Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $1.12 – $27.85 · fair‑value band $0.4250 – $0.8075 · the $1.93 price screens above the $0.6460 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow INmune Bio in your weekly email
Every Wednesday you see whether INmune Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Show more
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Stock analysis
INmune Bio Inc (INMB) currently trades at $1.93, while our model-based Fair Value estimate is $0.6460, 66.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.4250 (bear) to $0.8075 (bull), the price of $1.93 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
INmune Bio Inc reported revenue of $50.0K in FY2025 versus $181K in FY2021, a compound −27.5%/yr. Reported net income was −$45.9M in FY2025.
Key figures
Market cap $60.2M · EPS (TTM) $−0.6200 · Return on equity −74.8% · Return on assets (EBIT) −63.3% · Revenue growth (YoY) +257% · Free cash flow −$23.6M · Net cash $23.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 23% below its 52-week high and 72% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −67%, INMB screens richer than that median.
Fair Value models
Bear $0.4250Fair Value $0.6460Bull $0.8075
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−48.9%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−70.6%
’19
’21
’22
’23
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−112,016.1% (2020) → −61,738.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 584 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside−66.5% · Below median
Profitability
Return on assets−39.1% · Bottom 25%
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth257.1% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.56× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "INmune Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/INMB
Frequently asked questions
Is INmune Bio Inc (INMB) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.6460 versus a price of $1.93, about −67% upside (overvalued).
What is the fair value of INMB?
Our model-based fair value for INmune Bio Inc is $0.6460 (as of Sep 27, 2026), built from audited fundamentals. The current price: $1.93.
What is the quality score of INMB?
INmune Bio Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for INmune Bio Inc (INMB)?
Our model-based price target is the fair value of $0.6460 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.4250, optimistic scenario $0.8075. It is a calculation from audited fundamentals, not an analyst target.
What is the INmune Bio Inc stock forecast for 2026?
Our models put fair value at $0.6460, about −67% upside versus a price of $1.93 (overvalued). Cautious scenario $0.4250, optimistic scenario $0.8075. The calculation is refreshed regularly with new filings.
What is the intrinsic value of INmune Bio Inc (INMB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For INmune Bio Inc it is $0.6460 per share (as of Sep 27, 2026), against a price of $1.93. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is INmune Bio Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, INMB trades above its calculated fair value: price $1.93, fair value $0.6460, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INMB?
No. The price is what the market pays today ($1.93); the fair value is what the company's own numbers justify ($0.6460). For INmune Bio Inc the two are $1.28 per share apart. That gap is exactly why we show both numbers side by side.
How much is INmune Bio Inc worth?
The market values INmune Bio Inc at about $60.2M (market capitalisation, as of Sep 27, 2026). Per share that is $1.93; our models calculate a fair value of $0.6460 per share.
What do the bullish and bearish scenarios say about INMB?
Our models span a range for INmune Bio Inc: cautious scenario $0.4250, base $0.6460, optimistic $0.8075 per share (as of Sep 27, 2026, price $1.93). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of INmune Bio Inc (INMB)?
Balance-sheet figures for INmune Bio Inc (as of Sep 27, 2026): return on equity −74.8%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is INMB from its 52-week high?
INmune Bio Inc trades at $1.93, about 23% below its 52-week high of $2.51 and 72% above the low of $1.12 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6460 is for.
Which stocks are comparable to INmune Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is INmune Bio Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $1.93, calculated fair value $0.6460 (−67%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INMB calculated?
We run INmune Bio Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6460, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. INmune Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of INmune Bio Inc (INMB)?
The closing price on Oct 1, 2026 was $1.93. Our model-based fair value is $0.6460, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with INmune Bio Inc right now?
The price sits above even our optimistic bull case ($0.8075). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4250 to $0.8075) leaves room in how you read the outcome.
Key figures of INmune Bio Inc
How large is the market capitalisation of INmune Bio Inc (INMB)?
The market capitalisation of INmune Bio Inc is $60.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of INmune Bio Inc (INMB)?
Earnings per share at INmune Bio Inc are $−0.6200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of INmune Bio Inc (INMB)?
The return on equity (ROE) of INmune Bio Inc is −74.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of INmune Bio Inc (INMB)?
On an EBIT basis the return on assets of INmune Bio Inc is −63.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at INmune Bio Inc (INMB)?
Revenue at INmune Bio Inc is growing +257% versus a year earlier (3y avg −48.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does INmune Bio Inc (INMB) generate?
The free cash flow of INmune Bio Inc is −$23.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does INmune Bio Inc (INMB) hold?
INmune Bio Inc holds more cash than debt, $23.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch INmune Bio Inc in the live analysis
One click puts INmune Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026